Oludare ADEWUYI

Dr. Oludare ADEWUYI

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
OAOludare ADEWUYI
Oludare ADEWUYI
MBMuhammad Shakir Balogun
Muhammad Shakir Balogun
HOHirono Otomaru
Hirono Otomaru
AAAlash'le Abimiku
Alash'le Abimiku
AAAnthony Agbakizu Ahumibe
Anthony Agbakizu Ahumibe
LYLay Myint Yoshida
Lay Myint Yoshida
Information on circulating HBV (sub-)genotype, variants, and hepatitis D virus (HDV) coinfection, which vary by geographical area, is crucial for the efficient control and management of HBV. We investigated the genomic characteristics of HBV (with a prevalence of 8.1%) and the prevalence of HDV in Nigeria. We utilised 777 HBV-positive samples and epidemiological data from the two-stage sampled population-based, nationally representative Nigeria HIV/AIDS Indicator and Impact Survey conducted in 2018. We assessed 732 HBV DNA-extracted samples with detectable viral loads (VLs) for (sub-)genotypes and variants by whole-genome pre-amplification, nested PCR of the s-and pol-gene, and BigDye Terminator sequencing. We conducted HDV serology. In total, 19 out of the 36 + 1 states in Nigeria had a high prevalence of HBV (≥8%), with the highest prevalence (10.4%) in the north-central geopolitical zone. Up to 33.2% (95% CI 30.0–36.6) of the participants had detectable VLs of ≥300 copies/mL. The predominant circulating HBV genotype was E with 98.4% (95% CI 97.1–99.1), followed by A with 1.6% (95% CI 0.9–2.9). Drug-resistant associated variants and immune escape variants were detected in 9.3% and 0.4%, respectively. The seroprevalence of HDV was 7.34% (95% CI 5.5–9.2). Nigeria has subtype E as the major genotype with many variants.

5 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
OAOludare ADEWUYI
Oludare ADEWUYI
JYJoseph Yaria
Joseph Yaria
JOJames Aigboje Orevba
James Aigboje Orevba
PNPatrick Nguku
Patrick Nguku
MDMagbagbeola David Dairo
Magbagbeola David Dairo
To ensure the prevention of mother-to-child-transmission of HIV (MTCT), 81% of pregnant women received antiretroviral therapy (ART) in 2021 worldwide. Despite the global efforts to prevent MTCT of HIV, significant knowledge gaps persist among these women including a lack of basic knowledge of HIV and ART. This study aimed to determine the levels of HIV knowledge, knowledge of ART, and attitude toward ART in HIV-positive pregnant women in Kaduna State. It was a hospital-based, cross-sectional study among 318 HIV-positive pregnant women attending antenatal care in the nine selected hospitals using a three-stage sampling technique. Data was collected using the Open Data Kit. Up to 54.4% had a fair knowledge of ART while 75.4% of the respondents had good knowledge of HIV, and up to 98.6% had a positive attitude towards ART. Knowledge of ART and attitude to ART are positively influenced by receiving multiple counselling (p = 0.031, aOR = 6), being on ART for ≥ 2 years (p = 0.021, aOR = 6); and not taking unprescribed medications (p = 0.047, aOR = 17) respectively. Sustained, focused counselling and patient education are necessary to establish and optimise the required adherence in this group. Also, implement clear task-sharing strategies for health personnel to provide tailored services.